Skip to content
CNS Clinical Research

Las Vegas, Nevada

CNS clinical trials in Las Vegas, NV

45 CNS studies are recruiting participants at sites in Las Vegas as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.

Call (888) 520-7418
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Las Vegas at a glance

  • 45 studies are recruiting at a site in Las Vegas.
  • By phase: Phase 2 (13), Phase 3 (22), Phase 4 (5), No phase (2), Observational (3). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (41), university, hospital or other (4).
  • By research area: Depression (16), Parkinson's Disease (8), ADHD (6), Migraine (6), Schizophrenia (6), Multiple Sclerosis (3).
  • Most recent update to one of these records: November 16, 2026.

Depression studies recruiting in Las Vegas

Basic details from each study's public record (the 30 most recently updated of 45). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study site
    Vector Clinical Trials
    Registry record
    NCT07226661 · updated
  2. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 85
    • All sexes
    Sponsor
    Cybin IRL Limited
    Study site
    Redbird Research, LLC
    Registry record
    NCT06793397 · updated
  3. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Definium Therapeutics US, Inc.
    Study site
    Redbird Research
    Registry record
    NCT07592689 · updated
  4. ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    ACADIA Pharmaceuticals Inc.
    Study site
    Redbird Research LLC
    Registry record
    NCT07284667 · updated
  5. A Study of Brenipatide in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Vector Clinical Trials
    Registry record
    NCT07412756 · updated
  6. A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Vector Clinical Trials
    Registry record
    NCT07573176 · updated
  7. A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Tonix Pharmaceuticals, Inc.
    Registry record
    NCT07621237 · updated
  8. Study of ALTO-300 in MDD

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Alto Neuroscience
    Registry record
    NCT05922878 · updated
  9. ALTO-100 in Bipolar Disorder With Depression (BD-D)

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Alto Neuroscience
    Registry record
    NCT06656416 · updated
  10. Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07484217 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Las Vegas, NV on ClinicalTrials.gov.

Schizophrenia studies recruiting in Las Vegas

  1. A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

    • Phase 2
    • Ages 55 to 90
    • All sexes
    Sponsor
    MapLight Therapeutics
    Registry record
    NCT06887192 · updated
  2. A Study to Evaluate the Effect of KarXT on Urological Safety

    • Phase 4
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    IMA Clinical Research Las Vegas
    Registry record
    NCT07221877 · updated
  3. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

    • Phase 3
    • Ages 5 to 17
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    Clinical Research of Southern Nevada, LLC
    Registry record
    NCT06229210 · updated
  4. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    MapLight Therapeutics
    Registry record
    NCT07459647 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Las Vegas, NV on ClinicalTrials.gov.

ADHD studies recruiting in Las Vegas

  1. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

    • Phase 3
    • Ages 6 to 11
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717879 · updated
  2. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717892 · updated
  3. A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Otsuka Pharmaceutical Development & Commercialization, Inc.
    Study site
    Center for Psychiatry and Behavioral Medicine. Inc.
    Registry record
    NCT07759154 · updated
  4. A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Alkermes, Inc.
    Study site
    Alkermes Investigational Site
    Registry record
    NCT07755410 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Las Vegas, NV on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Las Vegas

  1. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Comprehensive Cancer Centers of Nevada ( Site 0015)
    Registry record
    NCT06841354 · updated
  2. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Optum Care Cancer Center ( Site 0050)
    Registry record
    NCT06966700 · updated
  3. A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Women's Cancer Center of Nevada ( Site 6011)
    Registry record
    NCT07216703 · updated
  4. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Cleveland Clinic Lou Ruvo
    Registry record
    NCT07174310 · updated
  5. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    • Phase 2
    • Ages 40 to 80
    • All sexes
    Sponsor
    Neuron23 Inc.
    Study site
    Cleveland Clinic
    Registry record
    NCT06680830 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Las Vegas, NV on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Las Vegas

  1. A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT06433752 · updated
  2. Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

    • Phase 3
    • Ages 40 to 70
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Cleveland Clinic Foundation
    Registry record
    NCT06846281 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Las Vegas, NV on ClinicalTrials.gov.

Migraine studies recruiting in Las Vegas

  1. A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Oasis Clinical Research
    Registry record
    NCT07816367 · updated
  2. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study sites
    AMR Clinical - Las Vegas · Excel Clinical Research · IMA Clinical Research - Las Vegas
    Registry record
    NCT07645924 · updated
  3. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study sites
    AMR Clinical - Las Vegas · Excel Clinical Research · IMA Clinical Research - Las Vegas
    Registry record
    NCT07674654 · updated
  4. A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine

    • Phase 4
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    M3 Wake Research - Las Vegas Rainbow
    Registry record
    NCT07609914 · updated
  5. Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Aspeya, Inc.
    Study site
    M3 Wake Research - Las Vegas Rainbow
    Registry record
    NCT07646613 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Las Vegas, NV on ClinicalTrials.gov.

Ask about studies near Las Vegas

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 520-7418

or send a short form

How should we reach you?

Call